# Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM)

> **NCT03502993** · — · COMPLETED · sponsor: **Imperial College London** · enrollment: 7247 (actual)

## Conditions studied

- Fever
- Infection
- Inflammation

## Interventions

- **DIAGNOSTIC_TEST:** Validation of biomarker

## Key facts

- **NCT ID:** NCT03502993
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-02
- **Primary completion:** 2021-01-25
- **Final completion:** 2021-12-31
- **Target enrollment:** 7247 (ACTUAL)
- **Last updated:** 2023-10-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502993, "Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03502993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*